Ipilimumab-induced immune-related renal failure - A case report

Patrick M. Forde, Kathy Rock, Graham Wilson, Kenneth J. O'Byrne

Research output: Contribution to journalArticlepeer-review

Abstract

Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 and has become the first immune checkpoint inhibitor to enter clinical practice, being recently approved for the treatment of metastatic melanoma. Immune toxicity due to ipilimumab causing colitis, hepatitis, dermatitis and hypophysitis is well-described. We report on a case of acute renal failure resolving rapidly with high-dose corticosteroid treatment highlighting the importance of vigilance for rarer immune-related toxicities as clinical experience with ipilimumab grows.

Original languageEnglish (US)
Pages (from-to)4607-4608
Number of pages2
JournalAnticancer Research
Volume32
Issue number10
StatePublished - Oct 1 2012

Keywords

  • Ipilimumab
  • Melanoma metastasis
  • Renal failure

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Ipilimumab-induced immune-related renal failure - A case report'. Together they form a unique fingerprint.

Cite this